Cargando…

Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection

Human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) develops in 1–5% of HTLV-1-infected individuals. Previous studies by us and others have shown that the expression of negative immune checkpoint receptors (NCRs) is significantly increased on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clements, Danielle M., Crumley, Brenndan, Chew, Glen M., Davis, Elijah, Bruhn, Roberta, Murphy, Edward L., Ndhlovu, Lishomwa C., Jain, Pooja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985073/ https://www.ncbi.nlm.nih.gov/pubmed/33767694 http://dx.doi.org/10.3389/fimmu.2021.608890

Ejemplares similares

Telomere length, proviral load and neurologic impairment in HTLV-1-and HTLV-2-infected humans
por: Usadi, Benjamin, et al.
Publicado: (2014)

Telomere Length, Proviral Load and Neurologic Impairment in HTLV-1 and HTLV-2-Infected Subjects
por: Usadi, Benjamin, et al.
Publicado: (2016)

HTLV-1 Tax Specific CD8+ T Cells Express Low Levels of Tim-3 in HTLV-1 Infection: Implications for Progression to Neurological Complications
por: Ndhlovu, Lishomwa C., et al.
Publicado: (2011)

A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections
por: Marqué, Lola, et al.
Publicado: (2021)

Novel perspectives on antisense transcription in HIV-1, HTLV-1, and HTLV-2
por: Lin, Edward, et al.
Publicado: (2022)

Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation
por: Eckert, F., et al.
Publicado: (2017)

HTLV-1 Tax Specific CD8+ T cells express low levels of Tim-3 in HTLV-1 infection: implications for progression to neurological complications
por: Leal, Fabio E, et al.
Publicado: (2011)

HTLV-1 Infection and Its Associated Diseases
por: Saito, Mineki, et al.
Publicado: (2012)

Pan-cancer analyses reveal the immunotherapeutic value of klotho
por: Liang, Jinghao, et al.
Publicado: (2022)

First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
por: Anna, François, et al.
Publicado: (2021)

Bioresponsive and immunotherapeutic nanomaterials to remodel tumor microenvironment for enhanced immune checkpoint blockade
por: Fang, Tianxu, et al.
Publicado: (2023)

Expansion in CD39(+) CD4(+) Immunoregulatory T Cells and Rarity of Th17 Cells in HTLV-1 Infected Patients Is Associated with Neurological Complications
por: Leal, Fabio E., et al.
Publicado: (2013)

Immunotherapeutic Applications of NK Cells
por: Davis, Carter T., et al.
Publicado: (2015)

Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
por: He, Mengni, et al.
Publicado: (2020)

Cotranscriptional Chromatin Remodeling by Small RNA Species: An HTLV-1 Perspective
por: Aliya, Nishat, et al.
Publicado: (2012)

Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
por: Mostafa, Ahmed A., et al.
Publicado: (2018)

Exosomal microRNAs in cancer: Potential biomarkers and immunotherapeutic targets for immune checkpoint molecules
por: Alotaibi, Faizah
Publicado: (2023)

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
por: Terenziani, Rita, et al.
Publicado: (2021)

Booster vaccines for COVID-19 vaccine breakthrough cases?
por: Nixon, Douglas F, et al.
Publicado: (2022)

Editorial: Immunotherapeutic and Immunoprophylactic Strategies for Infectious Diseases
por: Sautto, Giuseppe A., et al.
Publicado: (2020)

Increased Frequency of Tim-3 Expressing T Cells Is Associated with Symptomatic West Nile Virus Infection
por: Lanteri, Marion C., et al.
Publicado: (2014)

The Pleiotropic Effects of YBX1 on HTLV-1 Transcription
por: Smith, Susan, et al.
Publicado: (2023)

The latent HIV reservoir: current advances in genetic sequencing approaches
por: Moar, Preeti, et al.
Publicado: (2023)

Transcriptome analysis of HTLV-1-infected cells in comparison to the normal and Tax-expressing T cells
por: Singh, Shruti, et al.
Publicado: (2011)

Pulmonary function testing in HTLV-I and HTLV-II infected humans: a cohort study
por: Murphy, Edward L, et al.
Publicado: (2003)

Monitoring Circulating Immune Checkpoint Proteins as Predictors of Non-AIDS Morbid Events in People With HIV Initiating Antiretroviral Therapy
por: Premeaux, Thomas A, et al.
Publicado: (2022)

Comprehensive Pan-Cancer Analyses of Pyroptosis-Related Genes to Predict Survival and Immunotherapeutic Outcome
por: Wang, Qilin, et al.
Publicado: (2022)

Comparative virology of HTLV-1 and HTLV-2
por: Martinez, Michael P., et al.
Publicado: (2019)

Quantifying the efficacy of checkpoint inhibitors on CD8(+) cytotoxic T cells for immunotherapeutic applications via single-cell interaction
por: Sullivan, Matthew Ryan, et al.
Publicado: (2020)

Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?
por: Liu, Yongqing, et al.
Publicado: (2023)

Does HTLV-1 Infection Show Phenotypes Found in Sjögren’s Syndrome?
por: Nakamura, Hideki, et al.
Publicado: (2022)

Biochemical Characterization, Specificity and Inhibition Studies of HTLV-1, HTLV-2, and HTLV-3 Proteases
por: Kassay, Norbert, et al.
Publicado: (2021)

Immunotherapeutic Advancements for Glioblastoma
por: Ampie, Leonel, et al.
Publicado: (2015)

Editorial: Complement and Immunotherapeutics
por: Okrój, Marcin, et al.
Publicado: (2021)

Immunotherapeutic Advances for NSCLC
por: Massafra, Marco, et al.
Publicado: (2021)

Respiratory and Urinary Tract Infections, Arthritis, and Asthma Associated with HTLV-I and HTLV-II Infection
por: Murphy, Edward L., et al.
Publicado: (2004)

Pan‐Cancer analyses of Necroptosis‐Related genes as a potential target to predict immunotherapeutic outcome
por: Zhou, Zheng, et al.
Publicado: (2022)

Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma
por: Sun, Bao-Ye, et al.
Publicado: (2023)

Role of Natural Killer Cells in HIV-Associated Malignancies
por: Leal, Fabio E., et al.
Publicado: (2017)

HTLV-1, Immune Response and Autoimmunity
por: Quaresma, Juarez A S, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fgoco61p8n1ue5qkotv9sco0a1